DFTX Rule Check
Definium Therapeutics Inc against the rules: which it passes, where it lags and what to look at next.
- Price
- $36.51
- Market Cap
- $4.91 B
- Next Earnings
- In 9 Days
Flags First
- ProfitabilityFail
- DilutionFail
- Cash RunwayCaution
- Distance from 52-Week HighCaution
Fit ScoreNot Enough Data
Too few rules could be measured; the score does not give a verdict.
59% of Rules Measured · The ring's slices are the categories: length is weight, fill is score.
Company Analysis
- No report for this focus yet.
Claude writes a second opinion independent of the site's own analysis; while the market is open it reads the live price.
Categories
Elimination · PassTiny or thinly traded stocks move on a handful of orders; a position you cannot exit when needed is not worth holding.
Rule by Rule
Elimination
3 of 3 Measured- Market CapAt least $300M$4.91 BPass
- Share PriceAt least $5$36.51Pass
- Liquidity500K shares and $10M traded per day on average2.74 M SharesPass
Growth
0 of 4 Measured- Quarterly EPS GrowthAt least 10% year over year—No Data
- Quarterly Sales GrowthAt least 10% year over year—No Data
- Three-Year EPS GrowthAt least 10% annualized—No Data
- Source of GrowthSales should grow at least 5% while profit grows—No Data
Profitability
1 of 2 Measured- ProfitabilityPositive trailing twelve-month EPS− $3.43Fail
- MarginsGross, operating and net margins positive—No Data
Financial Health
3 of 3 Measured- Current RatioAt least 1 — current assets cover current liabilities6.95Pass
- Debt / EquityAt most 1; above 2 fails0.04Pass
- Cash RunwayPositive free cash flow or at least two years of cash6.5 YrsCaution
Price Strength
3 of 4 Measured- Versus the MarketSix-month return not behind the S&P 500+ 66.2 PtsPass
- Versus Its SectorSix-month return not behind the sector fund—No Data
- Distance from 52-Week LowAt least 30% above the low248.9%Pass
- Distance from 52-Week HighAt most 25% below the high26.5%Caution
Ownership
3 of 3 Measured- DilutionShare count up at most 2% a year+ 76.6%Fail
- Famous Fund InterestAmong tracked funds, adders not outnumbered by trimmers1 FundsPass
- Insider ActivityNo heavy net selling over six months+44Pass
Catalyst Signals
0 of 3 Measured- Analyst TrendShare of buy ratings rising over three months+ 0.4 PtsNo Data
- Upside to TargetAt least 10% to the average target—No Data
- Quality of the Last ReportEarnings analysis score of at least 60—No Data
In each lane the line is the rule's threshold, the dot is the stock's value and the bar between them is the gap. Market cap, price and volume use a log scale: one step is ten times. A value beyond the end sits at the edge as an open dot.
Rule Bench
- 9Passed
- 2Caution
- 2Failed
- 9No Data
Each lamp is a rule: green passed, amber caution, red failed, grey no data. Tap a station to see its rules.
Weaknesses
- Trailing EPS of − $3.43; the company is losing money.
- Share count up + 76.6% in a year; existing holders are being diluted.
- Burning cash; at this pace cash lasts about 6.5 years.
- The price is 26.5% below its 52-week high.
Strengths
- Market cap of $4.91 B, comfortably above the size floor.
- Share price of $36.51, outside penny-stock territory.
- About 2.74 M shares trade a day; positions open and close easily.
- Current ratio of 6.95; short-term obligations are well covered.
- Debt to equity of 0.04; a light debt load.
- Beat the S&P 500 by 66.2 points over six months.
- The price is 248.9% above its 52-week low.
- 1 tracked famous funds hold it and interest is not fading.
- Net insider buying over the last six months.
Next Steps
- The company is burning cash. Look for the funding plan (debt, share issuance, cash buffer) in the last report.
- The share count is rising. Check how much growth stays per share: buybacks or new issuance?
- Earnings in 9 days. The result can move the price sharply; account for that risk.
- Write down the concrete reason for growth: a new product, a contract, management or an industry shift. If you cannot say it in one sentence, waiting may be the better choice.
What You Should Check
- Is there a concrete reason for growth, and can you say it in one sentence?
- Where does the valuation sit against sector peers?
- Does the chart confirm the trend, or are you fighting a falling price?
- Is the position size within the loss you could bear if you are wrong?
The score averages the measurable rules with category weights: growth 30, price strength 20, profitability 15, health 15, ownership 10, catalysts 10. A pass counts in full, a caution half; rules we cannot measure stay out. A stock that hits an elimination rule is capped at 45. Growth above 300% counts as a base effect and is marked as a caution.
Sources: prices from Alpaca, fundamentals and analyst ratings from Finnhub, share counts from SEC filings, famous funds from 13F reports, targets and report scores from the site's own analyses.
This is not investment advice; it is a research tool that measures fit with the rules.
Alpaca · SIPUpdated 17:36 NY15 Minutes Delayed
To Understand This